Immunotherapy with Programmed Cell Death Protein/Programmed Cell Death Ligand 1 (PD-1/PD-L1) targeting antibodies has significantly improved clinical outcomes for patients with non-small cell lung cancer (NSCLC) and has become an integral part of standard treatment regimens. The gene discussed is CD274; the disease is non-small cell lung carcinoma.